This is the authors' abstract. We don't add key points for this paper.
Background: Hemorrhagic intracortical lesions produce persistent sensorimotor deficits.Reboxetine, a selective norepinephrine (NE) reuptake inhibitor, has emerged as a potential pharmacological strategy to promote functional recovery.Objective: The objective of this study was to evaluate the effects of acute and chronic reboxetine administration on motor performance and NE levels in a rat model of intracortical injury induced by ferrous chloride (FeCl 2 ).Material and methods: Fifty-seven male Wistar rats were assigned to control or lesion groups, receiving a FeCl 2 injection into the right primary motor cortex.Animals received reboxetine under acute or chronic treatment regimens.Sensorimotor performance was assessed on days 1 and 3 post-surgery, whereas NE levels in the pons and dentate gyrus were quantified on day 3 post-surgery.Results: Both treatment regimens reduced sensorimotor deficits.Acute reboxetine administration improved motor performance by day 3 and increased pontine NE levels exclusively in the contralateral hemisphere.In contrast, chronic treatment accelerated recovery from day 1 and increased pontine NE levels bilaterally.In addition, sensorimotor performance positively correlated with pontine NE concentrations in both regimens.Conclusions: Reboxetine promotes motor recovery following hemorrhagic intracortical injury.Chronic administration is more effective, producing earlier behavioral improvement directly associated with greater pontine NE availability.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ríos-Castañeda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: